Rigel Reports Availability of Veppanu for ER+/HER2-, ESR1-Mutated Breast Cancer

Shots: Rigel has reported the availability of Veppanu (vepdegestrant) by prescription in the US for the treatment of adults with ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer, with disease progression following ≥1L of endocrine therapy Veppanu (200mg, PO, QD) is an FDA-approved PROTAC, a class of targeted protein degraders that uses the body’s natural machinery to selectively eliminate disease-causing proteins rather than simply inhibit them In May 2026, Rigel entered into an exclusive, global license agreement with Arvinas & Pfizer to develop, manufacture & commercialize Veppanu   Ref: PRnewswire  |  Image: Rigel  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Rigel Reports Availability of Veppanu for ER+/HER2-, ESR1-Mutated Breast Cancer appeared first on PharmaShots.